Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Lineage Cell Therapeutics, Inc. (LCTX) had Free Cash Flow of $-19.44M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$6.61M |
|
$0.85M |
|
$0.07M |
|
$6.54M |
|
$13.16M |
|
$-6.55M |
|
$2.16M |
|
$-4.39M |
|
$-4.38M |
|
$0.89M |
|
$0.89M |
|
$0.89M |
|
$0.90M |
|
$-6.55M |
|
$-6.38M |
|
230.12M |
|
230.12M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$59.16M |
|
$2.57M |
|
$53.43M |
|
$112.58M |
|
$11.37M |
|
$0.03M |
|
$57.87M |
|
$69.24M |
|
$43.35M |
|
$0.97M |
|
$43.35M |
|
243.12M |
|
| Cash Flow Statement Financials | |
$-18.92M |
|
$-13.46M |
|
$26.95M |
|
$46.35M |
|
$41.32M |
|
$-5.03M |
|
$4.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.20 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
99.00% |
|
-99.09% |
|
-99.09% |
|
-- |
|
-66.40% |
|
12.88% |
|
|
Free Cash Flow |
$-19.44M |
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
7.42 |
|
12.14 |
|
2.06% |
|
91.58% |
|
0.79% |
|
2.06% |
|
$0.18 |
|
$-0.08 |
|
$-0.08 |
|